Screener / SEC EDGAR /CIK 0001420800 /10-K filed Feb 26, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Devices

Enovis CORP ENOV

Compare with peers Embed
Earnings releases

Latest results release: Nov 5, 2026

8-K item 2.02, exhibit 99

What ENOV's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

Adjusted EBITDA represents Adjusted net income excluding all Other (income) expense, net; interest, taxes, and depreciation and other amortization. release Nov 5, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 5, 2026 · EX-99.1

Enovis Announces Third Quarter 2026 Results

Open on SEC

Board of Directors approves new $200 million share repurchase authorization Dallas, TX, November 5, 2026 (GLOBE NEWSWIRE)—Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 2, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

Enovis’ third-quarter net sales of $559 million grew 2% on a reported basis and 5% on an organic basis from the same quarter in 2025. Third quarter results reflect continued execution in P&R and Recon and encouraging momentum in new product introductions. Compared to the same quarter in 2025, net sales in Recon grew 6% on a reported basis and 6% on an organic basis, and P&R declined 2% on a reported basis and grew 3% on an organic basis.

Enovis also reported a third-quarter net income of $3 million , or 0.6% of sales, and adjusted EBITDA of $104 million, or 18.5% of sales.

The Company reported third-quarter 2026 net income of $0.02 per share and adjusted net earnings per diluted share of $0.88. “Our third-quarter results reflect continued progress against our innovation-led strategy and the benefits of executing with greater alignment, accountability, and discipline,” said Damien McDonald, Chief Executive Officer of Enovis. “Growth was consistent with our expectations for the quarter, with continued share gains in Recon and steady performance in Prevention & Recovery.

The environment remains dynamic, including volatility and cost inflation in many markets. Despite these challenges, we are investing in the technologies that will define the next phase of our growth, including our agreement to acquire eCential Robotics, while maintaining strong cost and capital discipline. Our focus remains on continuously improving how we operate and execute to make our performance repeatable, and increasingly profitable.”

Enovis updated financial expectations for 2026. Revenue guidance is narrowed to a range of $2.32-2.35 billion, versus prior expectations of $2.31-2.37 billion. Revenue guidance incorporates 5% organic revenue growth, as compared to 4-6% previously. Adjusted EBITDA guidance is raised to a range of $428-438 million, as compared to the prior outlook of $425-435 million. The guidance ranges for revenue

and adjusted EBITDA are based on current exchange rates. Enovis now expects foreign currency to be a benefit to revenue growth of 0.5%-1.0%, as compared to 0.5%-1.5% previously. Full-year adjusted earnings per share guidance is raised from $3.52-3.73 to $3.58-3.79. Full year free cash flow conversion is expected to be 25% or higher.

Enovis also announced that its Board of Directors has approved a new share repurchase authorization of up to $200 million of the Company’s outstanding common stock. The new authorization replaces the Company’s existing $100 million share repurchase authorization. The timing and amount of any repurchases will be determined by management based on market conditions, the Company’s capital allocation priorities and other factors.

Investors can access the webcast via a link on the Enovis website, www.enovis.com . For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 317-5715 (International callers) and asked to be joined into the Enovis call. A link to a replay of the call will also be available on the Enovis website later in the day.

Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Discover more about Enovis at www.enovis.com.

Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares on ir.enovis.com.

This press release includes forward-looking statements, including forward- looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis’ plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements are based on Enovis’ current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis’ results to differ materially from current expectations include, but are not limited to, risks related to the Company’s planned acquisition of eCential and the expected timeline for completing the acquisition, the growth potential of eCential’s surgical robotics platform combined with the Company’s ARVIS® Augmented Reality System, planned funding for the acquisition, the financial and operational impact of the acquisition, including the anticipated impact on Adjusted EBITDA margins, plans, goals, objectives, outlook, expectations and intentions; Enovis’ integration of Lima; the impact of

public health emergencies and global pandemics; disruptions in the global economy caused by escalating geopolitical tensions including in connection with the ongoing conflicts between Russia and Ukraine and in the Middle East; macroeconomic conditions, including the impact of inflationary pressures; changes in government trade policies, including the implementation of tariffs ; the impact of a shutdown of the U.S. government or any future shutdowns; supply chain disruptions; increasing energy costs and availability concerns, particularly in the European market; other impacts on Enovis’ business and ability to execute business continuity plans; and the other factors detailed in Enovis’ reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K under the caption “Risk Factors,” as well as the other risks discussed in Enovis’ filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.

Enovis has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). These non-GAAP financial measures may include one or more of the following: adjusted net income from continuing operations (“Adjusted net income”), Adjusted net income per diluted share, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted gross profit, and Adjusted gross profit margin.

Adjusted net income and Adjusted net income per diluted share exclude net income attributable to noncontrolling interest from continuing operations, net of taxes; the effect of income (loss) from discontinued operations, net of taxes; restructuring charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; acquisition-related intangible asset amortization; strategic purchase of economic interest on future royalty payments; and property plant and equipment step-up depreciation; goodwill impairment charges; non-cash Other (income) expense, net; and include the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments. Enovis also presents Adjusted net income margin, which is subject to the same adjustments as Adjusted net income.

Adjusted EBITDA represents Adjusted net income excluding all Other (income) expense, net; interest, taxes, and depreciation and other amortization. Enovis presents Adjusted EBITDA margin, which is subject to the same adjustments as Adjusted EBITDA.

Adjusted gross profit represents gross profit excluding depreciation step-up of acquired fixed assets and the impact of restructuring charges. Adjusted gross profit margin is subject to the same adjustments as Adjusted gross profit.

Organic sales growth calculates sales growth period over period, after excluding the impact of acquisitions, divestitures, and foreign exchange rate fluctuations.

Free cash flow represents cash flow from operating activities less purchases of property, plant and equipment net of proceeds from sale of certain properties. Free cash flow conversion represents free cash flow divided by adjusted net income.

These non-GAAP financial measures assist Enovis management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Enovis management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this press release. Enovis does not provide reconciliations of adjusted EBITDA or adjusted earnings per share on a forward-looking basis to the closest GAAP financial measures, as such information is not available without unreasonable efforts on

a forward-looking basis due to uncertainties regarding, and the potential variability of, reconciling items excluded from these measures. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period.

(1) Net income (loss) from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net income (loss) from continuing operations less net income attributable to noncontrolling interest from continuing operations - net of taxes.

(2) Restructuring charges reflect costs associated with the Company’s restructuring programs to reduce the structural costs of the Company. For further information, see Note 10, “Accrued Liabilities - Accrued Restructuring Liability ” included in our Form 10-Q. Includes expenses of $1.5 million and $1.7 million classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended October 3, 2025, respectively. There were no similar charges for the three and nine months ended October 2, 2026.

(3) MDR and other costs includes (i) $0.4 million and $1.6 million for the three and nine months ended October 2, 2026 and $2.1 million and $7.6 million for the three and nine months ended October 3, 2025, respectively, in non-recurring costs specific to updating our quality system, product labeling, asset write- offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) $0.5 million and $1.2 million for the three and nine months ended October 2, 2026 and $0.4 million and $1.4 million for the three and nine months ended October 3, 2025, respectively, of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

(4) Includes $0.6 million and $1.9 million in PPE step-up depreciation in connection with acquired businesses for the three and nine months ended October 2, 2026 and $0.7 million and $1.9 million for the three and nine months ended October 3, 2025, respectively.

(5) Strategic transaction costs includes: (i) $9.2 million and $21.0 million for the three and nine months ended October 2, 2026 and $9.2 million and $28.1 million for the three and nine months ended October 3, 2025, respectively, related to non-recurring integration costs associated with the Lima Acquisition which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company. In each case, such costs relate solely to roles eliminated in connection with the integration of the Lima acquisition, and are non-recurring and not part of our normal business operations; (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $6.1 million and $6.5 million for the three and nine months ended October 2, 2026 and $6.1 million and $11.8 million for the three and nine months ended October 3, 2025, of non-recurring (non-Lima) acquisition integration costs, and other non-recurring project costs for global ERP rationalization and shared service center start-up, offset by a $5.7 million non-cash gain in the second quarter of 2026 from the reversal of a portion of a contingent consideration liability (See Note 11), and (iii) $0.3 million and $0.6 million for the three and nine months ended October 2, 2026 and $0.4 million and $1.3 million for the three and nine months ended October 3, 2025, respectively, related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

(6) Purchase of royalty interest represents the one-time, up-front expense incurred by the Company to acquire the economic rights to future royalties under product development agreements in connection with the termination of such agreements as part of a strategic shift to a new product development model. The Company believes that excluding the impact of such expense enhances comparability between periods, provides investors with a clear and meaningful view of our underlying business trends and aligns with how management evaluates the ongoing business performance.

(7) Other (income) expense, net includes the fair value gain adjustment for non- designated cross currency swaps in 2026. Includes the final fair value loss adjustment for the Contingent Acquisition Shares issued in the first quarter of 2025.

(8) The effective tax rates used to calculate adjusted net income and adjusted net income per share were 23.0% and 22.7% for the three and nine months ended October 2, 2026 and 21.8% and 22.6% for the three and nine months ended October 3, 2025.

(9) In conjunction with our Form 10-Q filing for the first quarter of 2026, we revised our definition of Adjusted Net Income and Adjusted Net Income Per Diluted Share to no longer adjust for inventory step-up charges. Adjusted Net Income in prior periods has been revised to reflect this change for consistency of presentation along with its impact on the effective tax rate which has been revised from 22.9%, as presented in our Form 8-K for the nine months ended October 3, 2025, to 22.6%. Accordingly, Adjusted Net Income for the nine months ended October 3, 2025 has been revised from $135.6 million or $2.36 per diluted share, respectively, as presented in our Form 8-K for the ended October 3, 2025, to $122.1 million, or $2.12 per diluted share, respectively, reflecting the removal of a $18.1 million adjustment for inventory step-up in connection with acquired businesses, resulting in a corresponding reduction to Adjusted net income margin from continuing operations for the nine months ended October 3, 2025 from 8.1%, as presented in our Form 8-K for the period ended October 3, 2025, to 7.3%. There was no adjustment for inventory step-up during the three months ended October 3, 2025 .

(1) Restructuring charges reflect costs associated with the Company’s restructuring programs to reduce the structural costs of the Company. For further information, see Note 10, “Accrued Liabilities - Accrued Restructuring Liability ” included in our Form 10-Q. Includes expenses of $1.5 million and $1.7 million classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended October 3, 2025, respectively. There were no similar charges for the three and nine months ended October 2, 2026.

(2) MDR and other costs includes (i) $0.4 million and $1.6 million for the three and nine months ended October 2, 2026 and $2.1 million and $7.6 million for the three and nine months ended October 3, 2025, respectively, in non-recurring costs specific to updating our quality system, product labeling, asset write- offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) $0.5 million and $1.2 million for the three and nine months ended October 2, 2026 and $0.4 million and $1.4 million for the three and nine months ended October 3, 2025, respectively, of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

(3) Strategic transaction costs includes: (i) $9.2 million and $21.0 million for the three and nine months ended October 2, 2026 and $9.2 million and $28.1 million for the three and nine months ended October 3, 2025, respectively, related to non-recurring integration costs associated with the Lima Acquisition which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company. In each case, such costs relate solely to roles eliminated in connection with the integration of the Lima acquisition, and are non-recurring and not part of our normal business operations; (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $6.1 million and $6.5 million for the three and nine months ended October 2, 2026 and $6.1 million and $11.8 million for the three and nine months ended October 3, 2025, of non-recurring (non-Lima) acquisition integration costs, and other non-recurring project costs for global ERP rationalization and shared service center start-up, offset by a $5.7 million non-cash gain in the second quarter of 2026 from the reversal of a portion of a contingent consideration liability (See Note 11), and (iii) $0.3 million and $0.6 million for the three and nine months ended October 2, 2026 and $0.4 million and $1.3 million for the three and nine months ended October 3, 2025, respectively, related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

(4) Purchase of royalty interest represents the one-time, up-front expense incurred by the Company to acquire the economic rights to future royalties under product development agreements in connection with the termination of such agreements as part of a strategic shift to a new product development model. The Company believes that excluding the impact of such expense enhances comparability between periods, provides investors with a clear and meaningful view of our underlying business trends and aligns with how management evaluates the ongoing business performance.

(5) In conjunction with our Form 10-Q filing for the first quarter of 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, Adjusted EBITDA for the nine months ended October 3, 2025 has been revised from $291.1 million, as presented in our Form 10-Q for the period ended October 3, 2025, to $273.0 million, reflecting the removal of a $18.1 million adjustment for inventory step-up in connection with acquired businesses resulting in a corresponding reduction to Adjusted EBITDA margin for the nine months ended October 3, 2025 from 17.4%, as presented in our Form 10-Q for the period ended October 3, 2025, to 16.3%. There was no adjustment for inventory step-up during the three months ended October 3, 2025 .

(1) In conjunction with our Form 10-Q filing for the first quarter of 2026, we revised our definition of Adjusted gross profit to no longer adjust for inventory step-up charges. Adjusted gross profit in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, Adjusted gross profit for the nine months ended October 3, 2025 has been revised from $1,017.3 million, as presented in our Form 8-K for the period ended October 3, 2025, to $999.2 million, reflecting the removal of a $18.1 million adjustment for inventory step-up in connection with acquired businesses, resulting in a corresponding reduction to Adjusted gross profit margin for the nine months ended October 3, 2025 from 60.8%, as presented in our Form 8-K for the period ended October 3, 2025, to 59.8%. There was no adjustment for inventory step-up during the three months ended October 3, 2025 .

Nine Months Ended October 2, 2026 October 3, 2025 ────────────────────────────────────────────────────────────────────────────── Cash flows from operating activities: Net loss $ -6,069 $ -663,166 Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and 217,884 217,366 amortization Impairment of — 548,442 goodwill Stock-based compensation 25,470 24,809 expense Non-cash 5,929 5,120 interest expense Fair value loss on contingent — 1,787 acquisition shares Deferred income -42,241 -565 tax benefit Loss on disposal of property, 960 1,129 plant and equipment Changes in operating assets and liabilities: Trade 7,588 -17 receivables, net Inventories, net -44,283 -33,153 Accounts payable 15,602 10,345 Other operating assets and -10,364 16,652 liabilities Net cash provided by 170,476 128,749 operating activities Cash flows from investing activities: Purchases of property, plant and -133,204 -141,122 equipment and intangibles Payments for acquisitions, net of cash -4,122 -26,859 received, and investments Cash received (paid) for net investment -3,283 1,601 hedge derivatives Net cash used in investing -140,609 -166,380 activities Cash flows from financing activities: Repayments of borrowings under -26,250 -15,000 term credit facility Proceeds from borrowings on revolving 172,000 177,000 credit facilities and other Repayments of borrowings on revolving -189,041 -136,862 credit facilities and other Payments of tax withholding for -1,473 -3,504 stock-based awards Proceeds from issuance of 1,354 1,318 common stock, net Deferred consideration -9,637 -2,437 payments and other Net cash provided by (used in) -53,047 20,515 financing activities Effect of foreign exchange rates on Cash -171 2,566 and cash equivalents Decrease in Cash and cash -23,351 -14,550 equivalents Cash and cash equivalents, 36,389 48,167 beginning of period Cash and cash equivalents, end $ 13,038 $ 33,617 of period

(1) Constant currency growth rate represents sales growth excluding the impact of foreign exchange rate fluctuations based on prior year sales valued at the current period foreign currency rates.

(2) Excludes the impact of foreign exchange rate fluctuations and acquisitions/divestitures, thus providing a measure of change due to factors such as price, product mix and volume.

(3) The three months ended October 3, 2025 include $13.8 million of sales from the October 2025 divestiture of the Company’s Dr. Comfort Footcare Solutions product line

(1) Constant currency growth rate represents sales growth excluding the impact of foreign exchange rate fluctuations based on prior year sales valued at the current period foreign currency rates.

(2) Excludes the impact of foreign exchange rate fluctuations and acquisitions/divestitures, thus providing a measure of change due to factors such as price, product mix and volume. (3) The nine months ended October 3, 2025 include $40.9 million of sales from the October 2025 divestiture of the Company’s Dr. Comfort Footcare Solutions product line.

(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions/divestitures, thus providing a measure of change due to factors such as price, product mix and volume.

(2) Represents the incremental sales as a result of acquisitions of businesses for twelve months from the acquisition date. Excludes (i) acquisitions of former distribution partners as such transactions primarily represent a shift from a third-party distribution model to a direct sales model, and (ii) acquisitions of intellectual property as such transactions involve the purchase of technologies that have not been commercialized.

(3) Represents the decrease in sales as a result of divestitures of businesses for twelve months from the divestiture date.

(4) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of change due to factors such as price, product mix and volume.

(2) Represents the incremental sales as a result of acquisitions of businesses for twelve months from the acquisition date. Excludes (i) acquisitions of former distribution partners as such transactions primarily represent a shift from a third-party distribution model to a direct sales model, and (ii) acquisitions of intellectual property as such transactions involve the purchase of technologies that have not been commercialized.

(3) Represents the decrease in sales as a result of divestitures of businesses for twelve months from the divestiture date.

(4) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

Full text with the tables
                                                                                
                  Enovis Announces Third Quarter 2026 Results                   
                                                                                
                                                                                
  •                                                                             
                                                                                
Third-quarter sales growth of 2% on a reported basis, 5% organic
                                                                                
  •                                                                             
                                                                                
Third-quarter Reconstructive sales growth of 6% on a reported and organic basis
                                                                                
  •                                                                             
                                                                                
Raising full-year 2026 guidance for adjusted EBITDA and adjusted EPS
                                                                                
  •                                                                             
                                                                                
Board of Directors approves new $200 million share repurchase authorization
Dallas, TX, November 5, 2026 (GLOBE NEWSWIRE)—Enovis™ Corporation (“Enovis” or
“the Company”) (NYSE: ENOV), an innovation-driven medical technology growth
company, today announced its financial results for the third quarter ended
October 2, 2026. The Company will host an investor conference call and live
webcast to discuss these results today at 8:30 am ET.
                                                                                
  Third Quarter 2026 Financial Results                                          
                                                                                
Enovis’ third-quarter net sales of $559 million grew 2% on a reported basis and
5% on an organic basis from the same quarter in 2025. Third quarter results
reflect continued execution in P&R and Recon and encouraging momentum in new
product introductions. Compared to the same quarter in 2025, net sales in Recon
grew 6% on a reported basis and 6% on an organic basis, and P&R declined 2% on a
reported basis and grew 3% on an organic basis.

Enovis also reported a third-quarter net income of $3 million , or 0.6% of
sales, and adjusted EBITDA of $104 million, or 18.5% of sales.

The Company reported third-quarter 2026 net income of $0.02 per share and
adjusted net earnings per diluted share of $0.88.
“Our third-quarter results reflect continued progress against our innovation-led
strategy and the benefits of executing with greater alignment, accountability,
and discipline,” said Damien McDonald, Chief Executive Officer of Enovis.
“Growth was consistent with our expectations for the quarter, with continued
share gains in Recon and steady performance in Prevention & Recovery.

The environment remains dynamic, including volatility and cost inflation in many
markets. Despite these challenges, we are investing in the technologies that
will define the next phase of our growth, including our agreement to acquire
eCential Robotics, while maintaining strong cost and capital discipline. Our
focus remains on continuously improving how we operate and execute to make our
performance repeatable, and increasingly profitable.”
                                                                                
  2026 Financial Outlook                                                        
                                                                                
Enovis updated financial expectations for 2026. Revenue guidance is narrowed to
a range of $2.32-2.35 billion, versus prior expectations of $2.31-2.37 billion.
Revenue guidance incorporates 5% organic revenue growth, as compared to 4-6%
previously. Adjusted EBITDA guidance is raised to a range of $428-438 million,
as compared to the prior outlook of $425-435 million. The guidance ranges for
revenue

and adjusted EBITDA are based on current exchange rates. Enovis now expects
foreign currency to be a benefit to revenue growth of 0.5%-1.0%, as compared to
0.5%-1.5% previously. Full-year adjusted earnings per share guidance is raised
from $3.52-3.73 to $3.58-3.79. Full year free cash flow conversion is expected
to be 25% or higher.
                                                                                
  Share Repurchase Authorization                                                
                                                                                
Enovis also announced that its Board of Directors has approved a new share
repurchase authorization of up to $200 million of the Company’s outstanding
common stock. The new authorization replaces the Company’s existing $100 million
share repurchase authorization. The timing and amount of any repurchases will be
determined by management based on market conditions, the Company’s capital
allocation priorities and other factors.
                                                                                
  Conference call and Webcast                                                   
                                                                                
Investors can access the webcast via a link on the Enovis website,
www.enovis.com . For those planning to participate on the call, please dial
(833) 685-0901 (U.S. callers) and (412) 317-5715 (International callers) and
asked to be joined into the Enovis call. A link to a replay of the call will
also be available on the Enovis website later in the day.
                                                                                
  About Enovis                                                                  
                                                                                
Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to
improving lives by developing clinically differentiated solutions that enhance
patient outcomes and restore motion for life. We partner with the brightest
minds in health to advance care that is smarter, personalized, and more
effective, while improving operational efficiency for surgeons and clinicians
around the world. Enovis solutions impact the well-being of millions of patients
wherever they are on their pathway to health. Discover more about Enovis at
www.enovis.com.
                                                                                
  Availability of Information on the Enovis Website                             
                                                                                
Investors and others should note that Enovis routinely announces material
information to investors and the marketplace using SEC filings, press releases,
public conference calls, webcasts and the Enovis Investor Relations website.
While not all of the information that the Company posts to the Enovis Investor
Relations website is of a material nature, some information could be deemed to
be material. Accordingly, the Company encourages investors, the media and others
interested in Enovis to review the information that it shares on ir.enovis.com.
                                                                                
  Forward-Looking Statements                                                    
                                                                                
This press release includes forward-looking statements, including forward-
looking statements within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include, but are not limited
to, statements concerning Enovis’ plans, goals, objectives, outlook,
expectations and intentions, and other statements that are not historical or
current fact. Forward-looking statements are based on Enovis’ current
expectations and involve risks and uncertainties that could cause actual results
to differ materially from those expressed or implied in such forward-looking
statements. Factors that could cause Enovis’ results to differ materially from
current expectations include, but are not limited to, risks related to the
Company’s planned acquisition of eCential and the expected timeline for
completing the acquisition, the growth potential of eCential’s surgical robotics
platform combined with the Company’s ARVIS® Augmented Reality System, planned
funding for the acquisition, the financial and operational impact of the
acquisition, including the anticipated impact on Adjusted EBITDA margins, plans,
goals, objectives, outlook, expectations and intentions; Enovis’ integration of
Lima; the impact of

public health emergencies and global pandemics; disruptions in the global
economy caused by escalating geopolitical tensions including in connection with
the ongoing conflicts between Russia and Ukraine and in the Middle East;
macroeconomic conditions, including the impact of inflationary pressures;
changes in government trade policies, including the implementation of tariffs ;
the impact of a shutdown of the U.S. government or any future shutdowns; supply
chain disruptions; increasing energy costs and availability concerns,
particularly in the European market; other impacts on Enovis’ business and
ability to execute business continuity plans; and the other factors detailed in
Enovis’ reports filed with the U.S. Securities and Exchange Commission (the
“SEC”), including its most recent Annual Report on Form 10-K under the caption
“Risk Factors,” as well as the other risks discussed in Enovis’ filings with the
SEC. In addition, these statements are based on assumptions that are subject to
change. This press release speaks only as of the date hereof. Enovis disclaims
any duty to update the information herein.
                                                                                
  Non-GAAP Financial Measures                                                   
                                                                                
Enovis has provided in this press release financial information that has not
been prepared in accordance with accounting principles generally accepted in the
United States of America (“non-GAAP”). These non-GAAP financial measures may
include one or more of the following: adjusted net income from continuing
operations (“Adjusted net income”), Adjusted net income per diluted share,
Adjusted EBITDA, Adjusted EBITDA margin, Adjusted gross profit, and Adjusted
gross profit margin.

Adjusted net income and Adjusted net income per diluted share exclude net income
attributable to noncontrolling interest from continuing operations, net of
taxes; the effect of income (loss) from discontinued operations, net of taxes;
restructuring charges; Medical Device Regulation (“MDR”) fees and other costs;
strategic transaction costs; stock-based compensation; acquisition-related
intangible asset amortization; strategic purchase of economic interest on future
royalty payments; and property plant and equipment step-up depreciation;
goodwill impairment charges; non-cash Other (income) expense, net; and include
the tax effect of adjusted pre-tax income at applicable tax rates and other tax
adjustments. Enovis also presents Adjusted net income margin, which is subject
to the same adjustments as Adjusted net income.

Adjusted EBITDA represents Adjusted net income excluding all Other (income)
expense, net; interest, taxes, and depreciation and other amortization. Enovis
presents Adjusted EBITDA margin, which is subject to the same adjustments as
Adjusted EBITDA.

Adjusted gross profit represents gross profit excluding depreciation step-up of
acquired fixed assets and the impact of restructuring charges. Adjusted gross
profit margin is subject to the same adjustments as Adjusted gross profit.

Organic sales growth calculates sales growth period over period, after excluding
the impact of acquisitions, divestitures, and foreign exchange rate
fluctuations.

Free cash flow represents cash flow from operating activities less purchases of
property, plant and equipment net of proceeds from sale of certain properties.
Free cash flow conversion represents free cash flow divided by adjusted net
income.

These non-GAAP financial measures assist Enovis management in comparing its
operating performance over time because certain items may obscure underlying
business trends and make comparisons of long-term performance difficult, as they
are of a nature and/or size that occur with inconsistent frequency or relate to
discrete restructuring plans that are fundamentally different from the ongoing
productivity improvements of the Company. Enovis management also believes that
presenting these measures allows investors to view its performance using the
same measures that the Company uses in evaluating its financial and business
performance and trends. Non-GAAP financial measures should not be considered in
isolation from, or as a substitute for, financial information calculated in
accordance with GAAP. Investors are encouraged to review the reconciliation of
these non-GAAP measures to their most directly comparable GAAP financial
measures. A reconciliation of non-GAAP financial measures presented above to
GAAP results has been provided in the financial tables included in this press
release. Enovis does not provide reconciliations of adjusted EBITDA or adjusted
earnings per share on a forward-looking basis to the closest GAAP financial
measures, as such information is not available without unreasonable efforts on

a forward-looking basis due to uncertainties regarding, and the potential
variability of, reconciling items excluded from these measures. These items are
uncertain, depend on various factors, and could have a material impact on GAAP
reported results for the guidance period.

Kyle Rose

Vice President, Investor Relations

Enovis Corporation
[email protected]
                                                                                
                               Enovis Corporation                               
                                                                                
                                                                                
                Condensed Consolidated Statements of Operations                 
                                                                                
                                                                                
                  Dollars in thousands, except per share data                   
                                                                                
                                  (Unaudited)                                   
                                                                                
           Three  Octob…          Octo…       Nine    Octo…          Octob…     
           Mont…      2,             3,       Months     2,              3,     
           Ended    2026           2025       Ended    2026            2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Net      $      558,7…       $  548,…       $       1,73…       $  1,672…     
  sales                                                                         
  Cost                                                                          
  of              218,8…          219,…               666,…          676,4…     
  sales                                                                         
  Gross           339,8…          328,…               1,06…          995,8…     
  prof…                                                                         
  Gross                                                                         
  prof…             60.8  %        59.9  %             61.5  %         59.5  %  
  marg…                                                                         
  Sell…                                                                         
  gene…                                                                         
  and             259,3…          263,…               805,…          799,7…     
  admi…                                                                         
  expe…                                                                         
  Rese…                                                                         
  and             31,275          29,7…               94,4…          88,967     
  deve…                                                                         
  expe…                                                                         
  Amor…                                                                         
  of              43,254          43,6…               126,…          128,4…     
  acqu…                                                                         
  inta…                                                                         
  Purc…                                                                         
  of                   —              —                   —          45,818     
  roya…                                                                         
  inte…                                                                         
  Rest…            2,568          1,910               10,1…           6,488     
  char…                                                                         
  Good…                                                                         
  impa…                —          548,…                   —          548,4…     
  char…                                                                         
  Oper…                                                                         
  inco…            3,375          -558…               27,3…          -622,…     
  (los…                                                                         
  Oper…                                                                         
  inco…              0.6  %       -101…  %              1.6  %        -37.2  %  
  (los…                                                                         
  marg…                                                                         
  Inte…                                                                         
  expe…            7,616          8,828               24,8…          27,310     
  net                                                                           
  Other                                                                         
  (inc…           -3,785           -448               -5,1…             508     
  expe…                                                                         
  net                                                                           
  Inco…                                                                         
  (los…                                                                         
  from                                                                          
  cont…             -456          -566…               7,643          -649,…     
  oper…                                                                         
  befo…                                                                         
  inco…                                                                         
  taxes                                                                         
  Inco…                                                                         
  tax             -1,679          4,005               15,8…          13,037     
  expe…                                                                         
  (ben…                                                                         
  Net                                                                           
  inco…                                                                         
  (los…            1,223          -570…               -8,2…          -662,…     
  from                                                                          
  cont…                                                                         
  oper…                                                                         
  Inco…                                                                         
  (los…                                                                         
  from                                                                          
  disc…            2,194            -40               2,155            -258     
  oper…                                                                         
  net                                                                           
  of                                                                            
  taxes                                                                         
  Net                                                                           
  inco…            3,417          -570…               -6,0…          -663,…     
  (los…                                                                         
  Net                                                                           
  inco…              0.6  %       -104…  %             -0.4  %        -39.7  %  
  (los…                                                                         
  marg…                                                                         
  Less:                                                                         
  net                                                                           
  inco…                                                                         
  attr…                                                                         
  to                                                                            
  nonc…                                                                         
  inte…              278            233                 746             685     
  from                                                                          
  cont…                                                                         
  oper…                                                                         
  - net                                                                         
  of                                                                            
  taxes                                                                         
  Net                                                                           
  inco…                                                                         
  (los…                                                                         
  attr…    $       3,139       $  -571…       $       -6,8…       $  -663,…     
  to                                                                            
  Enov…                                                                         
  Corp…                                                                         
  Net                                                                           
  inco…                                                                         
  (los…                                                                         
  per                                                                           
  share                                                                         
  -                                                                             
  basic                                                                         
  and                                                                           
  dilu…                                                                         
  Cont…    $        0.02       $  -9.99       $       -0.16       $  -11.64     
  oper…                                                                         
  Disc…    $        0.04       $      —       $        0.04       $       —     
  oper…                                                                         
  Cons…    $        0.06       $  -9.99       $       -0.12       $  -11.64     
  oper…                                                                         
                                                                                
                                                                                
                               Enovis Corporation                               
                                                                                
                                                                                
             Reconciliation of GAAP to Non-GAAP Financial Measures              
                                                                                
                                                                                
                   Dollars in millions, except per share data                   
                                                                                
                                  (Unaudited)                                   
                                                                                
           Three  Octob…          Octo…       Nine    Octo…          Octob…     
           Mont…      2,             3,       Months     2,              3,     
           Ended    2026           2025       Ended    2026            2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Adju…                                                                         
  Net                                                                           
  Inco…                                                                         
  and                                                                           
  Adju…                                                                         
  Net                                                                           
  Inco…                                                                         
  Per                                                                           
  Share                                                                         
  Net                                                                           
  inco…    $         3.4       $  -570…       $        -6.1       $  -663.2     
  (los…                                                                         
  (GAA…                                                                         
  Net                                                                           
  inco…                                                                         
  (los…              0.6  %       -104…  %             -0.4  %        -39.7  %  
  marg…                                                                         
  (GAA…                                                                         
  Net                                                                           
  loss                                                                          
  attr…                                                                         
  to                                                                            
  nonc…                                                                         
  inte…                                                                         
  from              -0.3           -0.2                -0.7            -0.7     
  cont…                                                                         
  oper…                                                                         
  -                                                                             
  net                                                                           
  of                                                                            
  taxes                                                                         
  Loss                                                                          
  (Inc…                                                                         
  from                                                                          
  disc…             -2.2              —                -2.2             0.3     
  oper…                                                                         
  net                                                                           
  of                                                                            
  taxes                                                                         
  Net                                                                           
  inco…                                                                         
  (los…                                                                         
  from                                                                          
  cont…    $         0.9       $  -571…       $        -9.0       $  -663.6     
  oper…                                                                         
  attr…                                                                         
  to                                                                            
  Enov…                                                                         
  Corp…                                                                         
  Rest…                                                                         
  char…              2.6            3.4                10.1             8.2     
  -                                                                             
  pret…                                                                         
  MDR                                                                           
  and                                                                           
  other              0.9            2.4                 2.8             9.0     
  costs                                                                         
  -                                                                             
  pret…                                                                         
  Amor…                                                                         
  of                                                                            
  acqu…             43.3           43.7               126.7           128.5     
  inta…                                                                         
  -                                                                             
  pret…                                                                         
  Good…                                                                         
  impa…                —          548.4                   —           548.4     
  char…                                                                         
  PPE                                                                           
  step…                                                                         
  depr…              0.6            0.7                 1.9             1.9     
  -                                                                             
  pret…                                                                         
  Stra…                                                                         
  tran…                                                                         
  costs             15.6           15.7                28.1            41.2     
  -                                                                             
  pret…                                                                         
  Purc…                                                                         
  of                   —              —                   —            45.8     
  roya…                                                                         
  inte…                                                                         
  Stoc…              7.5            9.0                25.2            25.0     
  comp…                                                                         
  Other                                                                         
  (inc…             -2.9           -0.4                -0.6             0.5     
  expe…                                                                         
  net(…                                                                         
  Tax              -17.1           -8.2               -30.0           -22.9     
  adju…                                                                         
  Adju…                                                                         
  net                                                                           
  inco…                                                                         
  from     $        51.4       $   43.5       $       155.2       $   122.1     
  cont…                                                                         
  oper…                                                                         
  (non…                                                                         
  Adju…                                                                         
  net                                                                           
  inco…                                                                         
  marg…              9.2  %         7.9  %              9.0  %          7.3  %  
  from                                                                          
  cont…                                                                         
  oper…                                                                         
  Weig…                                                                         
  shar…                                                                         
  outs…           57,672          57,1…               57,5…          57,029     
  -                                                                             
  dilu…                                                                         
  (GAA…                                                                         
  Net                                                                           
  loss                                                                          
  per                                                                           
  share                                                                         
  -        $        0.02       $  -9.99       $       -0.16       $  -11.64     
  dilu…                                                                         
  from                                                                          
  cont…                                                                         
  oper…                                                                         
  (GAA…                                                                         
  Adju…                                                                         
  weig…                                                                         
  shar…                                                                         
  outs…           58,493          57,7…               58,2…          57,558     
  -                                                                             
  dilu…                                                                         
  (non…                                                                         
  Adju…                                                                         
  net                                                                           
  inco…                                                                         
  per                                                                           
  share                                                                         
  -        $        0.88       $   0.75       $        2.67       $    2.12     
  dilu…                                                                         
  from                                                                          
  cont…                                                                         
  oper…                                                                         
  (non…                                                                         
                                                                                
__________

(1) Net income (loss) from continuing operations attributable to Enovis
Corporation for the respective periods is calculated using Net income (loss)
from continuing operations less net income attributable to noncontrolling
interest from continuing operations - net of taxes.

(2) Restructuring charges reflect costs associated with the Company’s
restructuring programs to reduce the structural costs of the Company. For
further information, see Note 10, “Accrued Liabilities - Accrued Restructuring
Liability ” included in our Form 10-Q. Includes expenses of $1.5 million and
$1.7 million classified as Cost of sales on the Company’s Condensed Consolidated
Statements of Operations for the three and nine months ended October 3, 2025,
respectively. There were no similar charges for the three and nine months ended
October 2, 2026.

(3) MDR and other costs includes (i) $0.4 million and $1.6 million for the three
and nine months ended October 2, 2026 and $2.1 million and $7.6 million for the
three and nine months ended October 3, 2025, respectively, in non-recurring
costs specific to updating our quality system, product labeling, asset write-
offs and product remanufacturing to comply with the medical device reporting
regulations and other requirements of the new medical device regulations in the
European Union for devices which were introduced to the market prior to the
regulation and (ii) $0.5 million and $1.2 million for the three and nine months
ended October 2, 2026 and $0.4 million and $1.4 million for the three and nine
months ended October 3, 2025, respectively, of expenses to resolve certain
infrequent, non-recurring regulatory or other legal matters. These costs are
classified as Selling, general and administrative expense on our Condensed
Consolidated Statements of Operations.

(4) Includes $0.6 million and $1.9 million in PPE step-up depreciation in
connection with acquired businesses for the three and nine months ended October
2, 2026 and $0.7 million and $1.9 million for the three and nine months ended
October 3, 2025, respectively.

(5) Strategic transaction costs includes: (i) $9.2 million and $21.0 million for
the three and nine months ended October 2, 2026 and $9.2 million and $28.1
million for the three and nine months ended October 3, 2025, respectively,
related to non-recurring integration costs associated with the Lima Acquisition
which includes (a) payroll and retention costs for roles eliminated in
connection with the integration of our recent acquisition of Lima where a legal
notice period was required prior to the employee’s separation from the Company,
or integration-related daily activities not related to former roles performed by
an employee during their legal notice period and prior to their separation from
the Company. In each case, such costs relate solely to roles eliminated in
connection with the integration of the Lima acquisition, and are non-recurring
and not part of our normal business operations; (b) professional and consulting
fees specifically incurred to consummate the acquisition and advise and
facilitate on post-acquisition integration matters including legal entity
consolidation, costs associated with rebranding and marketing acquired business
under Enovis name, such as marketing materials, trade show redesign costs and
product labeling; and (c) integration related costs associated with sales agent
and distributor network rationalization, including contract termination and
retention expenses, supply chain and portfolio integration, and quality
management system consolidation, (ii) $6.1 million and $6.5 million for the
three and nine months ended October 2, 2026 and $6.1 million and $11.8 million
for the three and nine months ended October 3, 2025, of non-recurring (non-Lima)
acquisition integration costs, and other non-recurring project costs for global
ERP rationalization and shared service center start-up, offset by a $5.7 million
non-cash gain in the second quarter of 2026 from the reversal of a portion of a
contingent consideration liability (See Note 11), and (iii) $0.3 million and
$0.6 million for the three and nine months ended October 2, 2026 and $0.4
million and $1.3 million for the three and nine months ended October 3, 2025,
respectively, related to the Separation of our former fabrication technology
business. These costs are classified as Selling, general and administrative
expense on our Condensed Consolidated Statements of Operations.

(6) Purchase of royalty interest represents the one-time, up-front expense
incurred by the Company to acquire the economic rights to future royalties under
product development agreements in connection with the termination of such
agreements as part of a strategic shift to a new product development model. The
Company believes that excluding the impact of such expense enhances
comparability between periods, provides investors with a clear and meaningful
view of our underlying business trends and aligns with how management evaluates
the ongoing business performance.

(7) Other (income) expense, net includes the fair value gain adjustment for non-
designated cross currency swaps in 2026. Includes the final fair value loss
adjustment for the Contingent Acquisition Shares issued in the first quarter of
2025.

(8) The effective tax rates used to calculate adjusted net income and adjusted
net income per share were 23.0% and 22.7% for the three and nine months ended
October 2, 2026 and 21.8% and 22.6% for the three and nine months ended October
3, 2025.

(9) In conjunction with our Form 10-Q filing for the first quarter of 2026, we
revised our definition of Adjusted Net Income and Adjusted Net Income Per
Diluted Share to no longer adjust for inventory step-up charges. Adjusted Net
Income in prior periods has been revised to reflect this change for consistency
of presentation along with its impact on the effective tax rate which has been
revised from 22.9%, as presented in our Form 8-K for the nine months ended
October 3, 2025, to 22.6%. Accordingly, Adjusted Net Income for the nine months
ended October 3, 2025 has been revised from $135.6 million or $2.36 per diluted
share, respectively, as presented in our Form 8-K for the ended October 3, 2025,
to $122.1 million, or $2.12 per diluted share, respectively, reflecting the
removal of a $18.1 million adjustment for inventory step-up in connection with
acquired businesses, resulting in a corresponding reduction to Adjusted net
income margin from continuing operations for the nine months ended October 3,
2025 from 8.1%, as presented in our Form 8-K for the period ended October 3,
2025, to 7.3%. There was no adjustment for inventory step-up during the three
months ended October 3, 2025 .
                                                                                
                               Enovis Corporation                               
                                                                                
                                                                                
             Reconciliation of GAAP to Non-GAAP Financial Measures              
                                                                                
                                                                                
                              Dollars in millions                               
                                                                                
                                  (Unaudited)                                   
                                                                                
           Three  Octob…          Octo…       Nine    Octo…          Octob…     
           Mont…      2,             3,       Months     2,              3,     
           Ended    2026           2025       Ended    2026            2025     
 ────────────────────────────────────────────────────────────────────────────── 
           -Dol…                                                                
           in                                                                   
           mill…                                                                
  Net                                                                           
  inco…    $         3.4       $  -570…       $        -6.1       $  -663.2     
  (los…                                                                         
  (GAA…                                                                         
  Net                                                                           
  inco…                                                                         
  (los…              0.6  %       -104…  %             -0.4  %        -39.7  %  
  marg…                                                                         
  (GAA…                                                                         
  Loss                                                                          
  (Inc…                                                                         
  from                                                                          
  disc…             -2.2              —                -2.2             0.3     
  oper…                                                                         
  net                                                                           
  of                                                                            
  taxes                                                                         
  Inco…                                                                         
  tax               -1.7            4.0                15.9            13.0     
  expe…                                                                         
  (ben…                                                                         
  Other                                                                         
  (inc…             -3.8           -0.4                -5.1             0.5     
  expe…                                                                         
  net                                                                           
  Inte…                                                                         
  expe…              7.6            8.8                24.8            27.3     
  net                                                                           
  Oper…                                                                         
  inco…    $         3.4       $  -558…       $        27.3       $  -622.1     
  (los…                                                                         
  (GAA…                                                                         
  Adju…                                                                         
  to                                                                            
  add:                                                                          
  Rest…              2.6            3.4                10.1             8.2     
  char…                                                                         
  MDR                                                                           
  and                0.9            2.4                 2.8             9.0     
  other                                                                         
  cost…                                                                         
  Stra…                                                                         
  tran…             15.6           15.7                28.1            41.2     
  cost…                                                                         
  Stoc…              7.5            9.0                25.2            25.0     
  comp…                                                                         
  Depr…                                                                         
  and               30.2           30.7                91.2            88.9     
  other                                                                         
  amor…                                                                         
  Amor…                                                                         
  of                43.3           43.7               126.7           128.5     
  acqu…                                                                         
  inta…                                                                         
  Good…                                                                         
  impa…                —          548.4                   —           548.4     
  char…                                                                         
  Purc…                                                                         
  of                   —              —                   —            45.8     
  roya…                                                                         
  inte…                                                                         
  Adju…                                                                         
  EBIT…    $       103.5       $   94.8       $       311.4       $   273.0     
  (non…                                                                         
  Adju…                                                                         
  EBIT…             18.5  %        17.3  %             18.0  %         16.3  %  
  marg…                                                                         
  (non…                                                                         
                                                                                
__________

(1) Restructuring charges reflect costs associated with the Company’s
restructuring programs to reduce the structural costs of the Company. For
further information, see Note 10, “Accrued Liabilities - Accrued Restructuring
Liability ” included in our Form 10-Q. Includes expenses of $1.5 million and
$1.7 million classified as Cost of sales on the Company’s Condensed Consolidated
Statements of Operations for the three and nine months ended October 3, 2025,
respectively. There were no similar charges for the three and nine months ended
October 2, 2026.

(2) MDR and other costs includes (i) $0.4 million and $1.6 million for the three
and nine months ended October 2, 2026 and $2.1 million and $7.6 million for the
three and nine months ended October 3, 2025, respectively, in non-recurring
costs specific to updating our quality system, product labeling, asset write-
offs and product remanufacturing to comply with the medical device reporting
regulations and other requirements of the new medical device regulations in the
European Union for devices which were introduced to the market prior to the
regulation and (ii) $0.5 million and $1.2 million for the three and nine months
ended October 2, 2026 and $0.4 million and $1.4 million for the three and nine
months ended October 3, 2025, respectively, of expenses to resolve certain
infrequent, non-recurring regulatory or other legal matters. These costs are
classified as Selling, general and administrative expense on our Condensed
Consolidated Statements of Operations.

(3) Strategic transaction costs includes: (i) $9.2 million and $21.0 million for
the three and nine months ended October 2, 2026 and $9.2 million and $28.1
million for the three and nine months ended October 3, 2025, respectively,
related to non-recurring integration costs associated with the Lima Acquisition
which includes (a) payroll and retention costs for roles eliminated in
connection with the integration of our recent acquisition of Lima where a legal
notice period was required prior to the employee’s separation from the Company,
or integration-related daily activities not related to former roles performed by
an employee during their legal notice period and prior to their separation from
the Company. In each case, such costs relate solely to roles eliminated in
connection with the integration of the Lima acquisition, and are non-recurring
and not part of our normal business operations; (b) professional and consulting
fees specifically incurred to consummate the acquisition and advise and
facilitate on post-acquisition integration matters including legal entity
consolidation, costs associated with rebranding and marketing acquired business
under Enovis name, such as marketing materials, trade show redesign costs and
product labeling; and (c) integration related costs associated with sales agent
and distributor network rationalization, including contract termination and
retention expenses, supply chain and portfolio integration, and quality
management system consolidation, (ii) $6.1 million and $6.5 million for the
three and nine months ended October 2, 2026 and $6.1 million and $11.8 million
for the three and nine months ended October 3, 2025, of non-recurring (non-Lima)
acquisition integration costs, and other non-recurring project costs for global
ERP rationalization and shared service center start-up, offset by a $5.7 million
non-cash gain in the second quarter of 2026 from the reversal of a portion of a
contingent consideration liability (See Note 11), and (iii) $0.3 million and
$0.6 million for the three and nine months ended October 2, 2026 and $0.4
million and $1.3 million for the three and nine months ended October 3, 2025,
respectively, related to the Separation of our former fabrication technology
business. These costs are classified as Selling, general and administrative
expense on our Condensed Consolidated Statements of Operations.

(4) Purchase of royalty interest represents the one-time, up-front expense
incurred by the Company to acquire the economic rights to future royalties under
product development agreements in connection with the termination of such
agreements as part of a strategic shift to a new product development model. The
Company believes that excluding the impact of such expense enhances
comparability between periods, provides investors with a clear and meaningful
view of our underlying business trends and aligns with how management evaluates
the ongoing business performance.

(5) In conjunction with our Form 10-Q filing for the first quarter of 2026, we
revised our definition of Adjusted EBITDA to no longer adjust for inventory
step-up charges. Adjusted EBITDA in prior periods has been revised to reflect
this change for consistency of presentation. Accordingly, Adjusted EBITDA for
the nine months ended October 3, 2025 has been revised from $291.1 million, as
presented in our Form 10-Q for the period ended October 3, 2025, to $273.0
million, reflecting the removal of a $18.1 million adjustment for inventory
step-up in connection with acquired businesses resulting in a corresponding
reduction to Adjusted EBITDA margin for the nine months ended October 3, 2025
from 17.4%, as presented in our Form 10-Q for the period ended October 3, 2025,
to 16.3%. There was no adjustment for inventory step-up during the three months
ended October 3, 2025 .
                                                                                
                               Enovis Corporation                               
                                                                                
   Reconciliation of Gross Margin (GAAP) to Adjusted Gross Margin (non-GAAP)    
                                                                                
                              Dollars in millions                               
                                                                                
                                  (Unaudited)                                   
                                                                                
           Three  Octob…          Octo…       Nine    Octo…          Octob…     
           Mont…      2,             3,       Months     2,              3,     
           Ended    2026           2025       Ended    2026            2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Net      $       558.7       $  548.9       $       1,73…       $  1,672…     
  sales                                                                         
  Gross    $       339.8       $  328.9       $       1,06…       $   995.8     
  prof…                                                                         
  Gross                                                                         
  prof…             60.8  %        59.9  %             61.5  %         59.5  %  
  marg…                                                                         
  (GAA…                                                                         
  Gross                                                                         
  prof…    $       339.8       $  328.9       $       1,06…       $   995.8     
  (GAA…                                                                         
  PPE                                                                           
  step…              0.6            0.6                 1.7             1.6     
  depr…                                                                         
  Rest…                —            1.5                   —             1.7     
  char…                                                                         
  Adju…                                                                         
  gross    $       340.4       $  331.0       $       1,06…       $   999.2     
  prof…                                                                         
  (Non…                                                                         
  Adju…                                                                         
  gross                                                                         
  prof…             60.9  %        60.3  %             61.6  %         59.8  %  
  marg…                                                                         
  (Non…                                                                         
                                                                                
__________

(1) In conjunction with our Form 10-Q filing for the first quarter of 2026, we
revised our definition of Adjusted gross profit to no longer adjust for
inventory step-up charges. Adjusted gross profit in prior periods has been
revised to reflect this change for consistency of presentation. Accordingly,
Adjusted gross profit for the nine months ended October 3, 2025 has been revised
from $1,017.3 million, as presented in our Form 8-K for the period ended October
3, 2025, to $999.2 million, reflecting the removal of a $18.1 million adjustment
for inventory step-up in connection with acquired businesses, resulting in a
corresponding reduction to Adjusted gross profit margin for the nine months
ended October 3, 2025 from 60.8%, as presented in our Form 8-K for the period
ended October 3, 2025, to 59.8%. There was no adjustment for inventory step-up
during the three months ended October 3, 2025 .
                                                                                
                               Enovis Corporation                               
                                                                                
                                                                                
                     Condensed Consolidated Balance Sheets                      
                                                                                
                                                                                
                   Dollars in thousands, except share amounts                   
                                                                                
                                  (Unaudited)                                   
                                                                                
                                       October 2, 2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  ASSETS                                                                        
  CURRENT ASSETS:                                                               
  Cash and cash equivalents         $           13,038    $             36,389  
  Trade receivables, less                                                       
  allowance for                                428,288                 442,786  
  credit losses of $26,462 and                                                  
  $25,609                                                                       
  Inventories, net                             620,155                 584,379  
  Prepaid expenses                              48,602                  42,283  
  Other current assets                         137,493                 101,222  
  Total current assets                       1,247,576               1,207,059  
  Property, plant and equipment,               526,315                 507,063  
  net                                                                           
  Goodwill                                     702,090                 718,299  
  Intangible assets, net                     1,093,942               1,236,713  
  Lease asset - right of use                    74,714                  72,256  
  Other assets                                  90,907                  93,347  
  Total assets                      $        3,735,544    $          3,834,737  
  LIABILITIES AND EQUITY                                                        
  CURRENT LIABILITIES:                                                          
  Current portion of long-term      $           35,000    $             35,000  
  debt                                                                          
  Accounts payable                             200,449                 187,531  
  Accrued liabilities                          344,389                 375,943  
  Total current liabilities                    579,838                 598,474  
  Long-term debt, less current               1,223,261               1,261,793  
  portion                                                                       
  Non-current lease liability                   59,985                  58,000  
  Other liabilities                            376,877                 424,568  
  Total liabilities                          2,239,961               2,342,835  
  Equity:                                                                       
  Common stock, $0.001 par                                                      
  value;                                                                        
  133,333,333 shares authorized;                                                
  57,694,452 and 57,194,781                                                     
  shares issued                                     58                      57  
  and outstanding as of October                                                 
  2, 2026                                                                       
  and December 31, 2025,                                                        
  respectively                                                                  
  Additional paid-in capital                 3,073,646               3,048,414  
  Accumulated deficit                       -1,474,278              -1,467,463  
  Accumulated other                           -106,185                 -91,363  
  comprehensive loss                                                            
  Total Enovis Corporation                   1,493,241               1,489,645  
  equity                                                                        
  Noncontrolling interest                        2,342                   2,257  
  Total equity                               1,495,583               1,491,902  
  Total liabilities and equity      $        3,735,544    $          3,834,737  
                                                                                
                                                                                
                               Enovis Corporation                               
                                                                                
                                                                                
                Condensed Consolidated Statements of Cash Flows                 
                                                                                
                                                                                
                              Dollars in thousands                              
                                                                                
                                  (Unaudited)                                   
                                                                                
                      Nine Months Ended  October 2, 2026       October 3, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Cash flows from                                                               
  operating                                                                     
  activities:                                                                   
  Net loss            $                           -6,069    $         -663,166  
  Adjustments to                                                                
  reconcile net                                                                 
  loss to net                                                                   
  cash provided by                                                              
  operating                                                                     
  activities:                                                                   
  Depreciation and                               217,884               217,366  
  amortization                                                                  
  Impairment of                                        —               548,442  
  goodwill                                                                      
  Stock-based                                                                   
  compensation                                    25,470                24,809  
  expense                                                                       
  Non-cash                                         5,929                 5,120  
  interest expense                                                              
  Fair value loss                                                               
  on contingent                                        —                 1,787  
  acquisition                                                                   
  shares                                                                        
  Deferred income                                -42,241                  -565  
  tax benefit                                                                   
  Loss on disposal                                                              
  of property,                                       960                 1,129  
  plant and                                                                     
  equipment                                                                     
  Changes in                                                                    
  operating assets                                                              
  and                                                                           
  liabilities:                                                                  
  Trade                                            7,588                   -17  
  receivables, net                                                              
  Inventories, net                               -44,283               -33,153  
  Accounts payable                                15,602                10,345  
  Other operating                                                               
  assets and                                     -10,364                16,652  
  liabilities                                                                   
  Net cash                                                                      
  provided by                                    170,476               128,749  
  operating                                                                     
  activities                                                                    
  Cash flows from                                                               
  investing                                                                     
  activities:                                                                   
  Purchases of                                                                  
  property, plant                                                               
  and                                           -133,204              -141,122  
  equipment and                                                                 
  intangibles                                                                   
  Payments for                                                                  
  acquisitions,                                                                 
  net of cash                                     -4,122               -26,859  
  received, and                                                                 
  investments                                                                   
  Cash received                                                                 
  (paid) for net                                                                
  investment                                      -3,283                 1,601  
  hedge                                                                         
  derivatives                                                                   
  Net cash used in                                                              
  investing                                     -140,609              -166,380  
  activities                                                                    
  Cash flows from                                                               
  financing                                                                     
  activities:                                                                   
  Repayments of                                                                 
  borrowings under                               -26,250               -15,000  
  term                                                                          
  credit facility                                                               
  Proceeds from                                                                 
  borrowings on                                                                 
  revolving                                      172,000               177,000  
  credit                                                                        
  facilities and                                                                
  other                                                                         
  Repayments of                                                                 
  borrowings on                                                                 
  revolving                                     -189,041              -136,862  
  credit                                                                        
  facilities and                                                                
  other                                                                         
  Payments of tax                                                               
  withholding for                                 -1,473                -3,504  
  stock-based                                                                   
  awards                                                                        
  Proceeds from                                                                 
  issuance of                                      1,354                 1,318  
  common stock,                                                                 
  net                                                                           
  Deferred                                                                      
  consideration                                   -9,637                -2,437  
  payments and                                                                  
  other                                                                         
  Net cash                                                                      
  provided by                                                                   
  (used in)                                      -53,047                20,515  
  financing                                                                     
  activities                                                                    
  Effect of                                                                     
  foreign exchange                                                              
  rates on Cash                                     -171                 2,566  
  and cash                                                                      
  equivalents                                                                   
  Decrease in Cash                                                              
  and cash                                       -23,351               -14,550  
  equivalents                                                                   
  Cash and cash                                                                 
  equivalents,                                    36,389                48,167  
  beginning of                                                                  
  period                                                                        
  Cash and cash                                                                 
  equivalents, end    $                           13,038    $           33,617  
  of period                                                                     
                                                                                
                                                                                
                               Enovis Corporation                               
                                                                                
                                                                                
                  GAAP Net Sales and Growth Rate Summary - QTD                  
                                                                                
                                                                                
                              Dollars in millions                               
                                                                                
                                  (Unaudited)                                   
                                                                                
        Thr…                                                                    
        Mon…                                                                    
        End…                                                                    
        Oct…                                                                    
        2,                                        Con…                          
  P…    2026         Oct…                         Cur…            Org…          
  &     (In          3,           Gro…            Gro…            Gro…          
  R…    mil…         2025         Rate            Rat…            Rat…          
 ────────────────────────────────────────────────────────────────────────────── 
  U…                                                                            
  B…    $     13…    $     12…          4.5  %          4.5  %          4.5  %  
  &                                                                             
  S…                                                                            
  U…                                                                            
  O…          61…          71…          -1…  %          -1…  %          5.1  %  
  P…                                                                            
  I…          91…          92…          -1…  %          -0…  %          -0…  %  
  P…                                                                            
  T…                                                                            
  P…          28…          29…          -1…  %          -1…  %          3.0  %  
  &                                                                             
  R…                                                                            
  R…                                                                            
  U…          13…          12…          4.9  %          4.9  %          4.9  %  
  R…                                                                            
  I…          13…          12…          7.0  %          7.8  %          7.8  %  
  R…                                                                            
  T…          27…          25…          6.0  %          6.3  %          6.3  %  
  R…                                                                            
  T…    $     55…    $     54…          1.8  %          2.1  %          4.6  %  
                                                                                
(1) Constant currency growth rate represents sales growth excluding the impact
of foreign exchange rate fluctuations based on prior year sales valued at the
current period foreign currency rates.

(2) Excludes the impact of foreign exchange rate fluctuations and
acquisitions/divestitures, thus providing a measure of change due to factors
such as price, product mix and volume.

(3) The three months ended October 3, 2025 include $13.8 million of sales from
the October 2025 divestiture of the Company’s Dr. Comfort Footcare Solutions
product line
                                                                                
                               Enovis Corporation                               
                                                                                
                                                                                
                  GAAP Net Sales and Growth Rate Summary - YTD                  
                                                                                
                                                                                
                              Dollars in millions                               
                                                                                
                                  (Unaudited)                                   
                                                                                
        Nine                                                                    
        Mon…                                                                    
        End…                                                                    
        Oct…                                                                    
        2,                                        Con…                          
  P…    2026         Oct…                         Cur…            Org…          
  &     (In          3,           Gro…            Gro…            Gro…          
  R…    mil…         2025         Rate            Rat…            Rat…          
 ────────────────────────────────────────────────────────────────────────────── 
  U…                                                                            
  B…    $     37…    $     36…          3.4  %          3.4  %          3.4  %  
  &                                                                             
  S…                                                                            
  U…                                                                            
  O…          17…          20…          -1…  %          -1…  %          4.2  %  
  P…                                                                            
  I…          29…          28…          4.0  %          0.5  %          0.1  %  
  P…                                                                            
  T…                                                                            
  P…          84…          85…          -1…  %          -2…  %          2.5  %  
  &                                                                             
  R…                                                                            
  R…                                                                            
  U…          42…          39…          6.6  %          6.6  %          6.6  %  
  R…                                                                            
  I…          46…          42…          9.7  %          5.5  %          5.5  %  
  R…                                                                            
  T…          88…          81…          8.2  %          6.0  %          6.0  %  
  R…                                                                            
  T…    $     1,…    $     1,…          3.5  %          1.9  %          4.2  %  
                                                                                
(1) Constant currency growth rate represents sales growth excluding the impact
of foreign exchange rate fluctuations based on prior year sales valued at the
current period foreign currency rates.

(2) Excludes the impact of foreign exchange rate fluctuations and
acquisitions/divestitures, thus providing a measure of change due to factors
such as price, product mix and volume.
(3) The nine months ended October 3, 2025 include $40.9 million of sales from
the October 2025 divestiture of the Company’s Dr. Comfort Footcare Solutions
product line.
                                                                                
                               Enovis Corporation                               
                                                                                
                                                                                
                              Change in Net Sales                               
                                                                                
                                                                                
                              Dollars in millions                               
                                                                                
                                  (Unaudited)                                   
                                                                                
       N…                                                                       
       S…                                                                       
       P…                                                                       
       a…                                                T…                     
       R…                       R…                       E…                     
 ────────────────────────────────────────────────────────────────────────────── 
       $          C…            $          C…            $          C…          
                  %                        %                        %           
  …                                                                             
  …                                                                             
  …                                                                             
  …    $   29…                  $   25…                  $   54…                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        8.7        3.0  %        16…        6.3  %        25…        4.6  %  
  …                                                                             
  …          —          —  %          —          —  %          —          —  %  
  …        -1…        -4…  %          —          —  %        -1…        -2…  %  
  …                                                                             
  …        -0…        -0…  %        -1…        -0…  %        -1…        -0…  %  
  …                                                                             
           -5…        -1…  %        15…        6.0  %        9.8        1.8  %  
  …                                                                             
  …                                                                             
  …                                                                             
  …    $   28…                  $   27…                  $   55…                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
                                                                                
(1) Excludes the impact of foreign exchange rate fluctuations and
acquisitions/divestitures, thus providing a measure of change due to factors
such as price, product mix and volume.

(2) Represents the incremental sales as a result of acquisitions of businesses
for twelve months from the acquisition date. Excludes (i) acquisitions of former
distribution partners as such transactions primarily represent a shift from a
third-party distribution model to a direct sales model, and (ii) acquisitions of
intellectual property as such transactions involve the purchase of technologies
that have not been commercialized.

(3) Represents the decrease in sales as a result of divestitures of businesses
for twelve months from the divestiture date.

(4) Represents the difference between prior year sales valued at the actual
prior year foreign exchange rates and prior year sales valued at current year
foreign exchange rates.
                                                                                
       Net                                                                      
       Sa…                                                                      
       Pr…                                                                      
       and                                               To…                    
       Re…                      Re…                      En…                    
 ────────────────────────────────────────────────────────────────────────────── 
       $          Ch…           $          Ch…           $          Ch…         
                  %                        %                        %           
  …                                                                             
  …                                                                             
  …                                                                             
  …    $    8…                  $    8…                  $    1…                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …         2…         2…  %         4…         6…  %         7…         4…  %  
  …                                                                             
  …         1…         0…  %          —          —  %         1…         0…  %  
  …         -…         -…  %          —          —  %         -…         -…  %  
  …                                                                             
  …         9…         1…  %         1…         2…  %         2…         1…  %  
  …                                                                             
            -…         -…  %         6…         8…  %         5…         3…  %  
  …                                                                             
  …                                                                             
  …                                                                             
  …    $    8…                  $    8…                  $    1…                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
                                                                                
(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions,
thus providing a measure of change due to factors such as price, product mix and
volume.

(2) Represents the incremental sales as a result of acquisitions of businesses
for twelve months from the acquisition date. Excludes (i) acquisitions of former
distribution partners as such transactions primarily represent a shift from a
third-party distribution model to a direct sales model, and (ii) acquisitions of
intellectual property as such transactions involve the purchase of technologies
that have not been commercialized.

(3) Represents the decrease in sales as a result of divestitures of businesses
for twelve months from the divestiture date.

(4) Represents the difference between prior year sales valued at the actual
prior year foreign exchange rates and prior year sales valued at current year
foreign exchange rates.

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ENOV/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.